Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

COMPARE Study: A Study to Compare the Renal Safety of Bondronat (Ibandronate) and Zoledronate in Patients With Multiple Myeloma

Status: Recruiting

Protocol number: ML18508

Sponsor: Hoffmann-La Roche AG

Company division: Pharmaceutical

Official Scientific Title: COMPARE: A randomized, open-label study to compare the nephrotoxicity of Bondronat and zoledronate in patients with multiple myeloma

Brief summary: This study will compare the effect of intravenous Bondronat and zoledronate on renal toxicity, in terms of serum creatinine levels, and efficacy, in terms of skeletal events, in patients with multiple myeloma. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals. Target sample size is 448.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Multiple Myeloma

Intervention type: Drug

Intervention name: ibandronate[Bondronat]

Primary outcome: 1. Renal safety: number of patients with a pre-specified increase from baseline in serum creatinine at week 96

Key secondary outcomes: 1. Efficacy: time until first skeletal event, number of skeletal events, proportion of patients with >=1 skeletal event Safety: frequency of dose reduction under zoledronate, creatinine clearance, incidence of osteonecrosis of the jaw

Inclusion criteria:

  • adult patients, >=18 years of age;
  • confirmed multiple myeloma (stage II and III) where treatment with bisphosphonates is indicated,

Exclusion criteria:

  • previous treatment with Bondronat or zoledronate within the last 12 months;
  • renal insufficiency;
  • presence of secondary malignant neoplasms, except for basalioma or cervical cancer in situ;
  • hypersensitivity to bondronat, zolendronate or other bisphosphonates.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: January, 2006

Trial registration date: 03/10/2006

Date last updated: 12/2/2008


Link to trial result

This trial is being conducted at the following locations:

Germany

  • Aschaffenburg
  • Augsburg
  • Berlin
  • Bremen
  • Duisburg
  • Essen
  • Esslingen
  • Frankfurt Am Main
  • Göttingen
  • Güstrow
  • Gütersloh
  • Hamburg
  • Hamm
  • Hannover
  • Herne
  • Jena
  • Karlsruhe
  • Kassel
  • Koblenz
  • Köln
  • Leer
  • Leipzig
  • Ludwigshafen
  • Magdeburg
  • Minden
  • München
  • Münster
  • Neumünster
  • Offenbach
  • Offenburg
  • Oldenburg
  • Stuttgart
  • Weiden
  • Wiesbaden
  • Würzburg
  • Zwickau

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply